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The synthesis of dehaloperophoramidine, a non-halogenated deriva-
tive of the marine natural product perophoramidine, and its biological
activity towards HCT116, HT29 and LoVo colorectal carcinoma cells
is reported. A [3,3]-Claisen rearrangement and an epoxide opening/
allylsilylation reaction installed the contiguous all-carbon quaternary
stereocentres with the required relative stereochemistry.
The natural product (+)-perophoramidine (1) was isolated by Ireland
from the marine ascidian Perophora namei.1 The authors also
reported the structure of dehaloperophoramidine (2), which they
obtained via transfer hydrogenation of (+)-1. These interesting
alkaloids are structurally related to a more complex family of natural
products that includes communesin F (3).2 Targets, including 1, 2
and 3, that possess contiguous all-carbon quaternary stereocentres
present a significant synthetic challenge.3 The presence of this
structural unit and the anticancer activity reported for 1 has led
to several total and formal syntheses.4 Previous syntheses of 2
have involved a spirocyclisation of a 2-thiotryptamine analogue,5
a dearomatising arylation of a quinoline6 and an eﬃcient
synthesis from a commercially available indigo dye.7
In work aimed at the synthesis of the communesins, we have
explored a [3,3]-Claisen approach to establish the required C7
stereocentre in 3 (Fig. 1).8 In the first part of this new report we
describe a significant extension of this work resulting in the
large scale synthesis (62 grams) and resolution of a novel ketone
using our [3,3]-Claisen rearrangement method (Scheme 1). This
highly eﬃcient sequence, that does not require chromatographic
purification in any of the first five steps, enables access to
enantio-enriched ketones. Whilst we view these ketones as
flexible starting points for the synthesis of a number of optically
pure complex ring systems, here we report conversion of racemic
material to 2.
Our retrosynthetic analysis of 2 (Scheme 1) identified lactam
4 as the cornerstone of the approach. Lactam 4 was viewed as
accessible from diallyl-substituted alcohol 5, which contains
both the required C-10b and C-11 stereocentres. A key challenge
in this part of the synthesis was the need to diﬀerentiate between
the two allyl groups in 5. This was achieved using two diﬀerent
selective iodocyclisation protocols. Whilst this transformation is
precedented in simpler systems,9 it has been used sparingly
in the synthesis of more complex alkaloid-based structures.10
Fig. 1 The structures of (+)-perophoramidine (1), (+)-dehaloperophoramidine
(2) and communesin F (3).
Scheme 1 Retrosynthetic analysis of 2 starting from commercially avail-
able 7 and 8.
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Alcohol 5 could be prepared from allyl-ketone 6, which itself
could be constructed from commercially available 7 and 8.
The key challenge in the conversion of 6 to 5 is the incorpora-
tion of the second contiguous all carbon stereogenic centre with the
required relative stereochemistry. Conversion of the ketone in 6 to
the corresponding epoxide was planned. Subsequent Lewis acid
catalysed epoxide opening followed by trapping with allylsilane was
predicted to lead to 5 with the approach of the allyl nucleophile
occurring from the opposite face to the allyl group that is
already present. This reaction, which we refer to as a modified
Hosomi–Sakurai reaction,11 has been used in natural product
synthesis,12 but to the best of our knowledge has not been used
in the construction of contiguous all-carbon quaternary centres.
Alternative approaches to lactam 4 involving the early development
of the allyl group in 6 or alkylation of a C11-based ester were
explored but were either ultimately unsuccessful or led to signifi-
cantly longer reaction sequences (data not shown).
The C10b stereocentre in 6 was installed in 5 steps from 7 and
8 as described in Scheme 2. After coupling of 7 and 8 to give 9, the
tetracyclic system was formed using a high temperature electro-
philic aromatic substitution reaction (see Scheme S1 (ESI†)13 for
additional studies). The cyclisation was scalable up to 100 g with
no detrimental eﬀect on the yield. Functional group manipula-
tions then enabled the preparation, via 10, of the [3,3]-Claisen
rearrangement substrate 11. Highly eﬃcient conversion of 11
to the required novel ketone 6 occurred on heating in toluene for
1.5 hours in 88% yield. This reaction was robust and scalable with
62 g of 6 being prepared in a single batch and without the need for
purification by column chromatography at any stage. Ketone 6
could be resolved by treatment with (R)-tert-butanesulfinamide (12)
to generate the readily separable diastereomeric imines 13 and 14
(Scheme 3). This approach was inspired by the reported resolution
of a ketone-containing intermediate en route to epiboxidine.14
Hydrolysis of imines 13 and 14 with 12 M HCl in MeOH gave
(R)-6 and (S)-6 respectively in 499% ee after recrystallisation
(confirmed by chiral HPLC analysis13). The absolute configuration
of the intermediate imines 13 and 14were assigned following X-ray
crystallographic analysis of 1515 which was obtained following
diastereoselective reduction of 14 with NaBH4 (Scheme 3). The
X-ray analysis indicated that the absolute configuration of
the C10b stereogenic centre in 15 (and hence in 14) was (R).
Hydrolysis of imine 14 therefore provided the (S)-enantiomer of
6 (and 13 gave (R)-6). Whilst (R)-6 and (S)-6 have been prepared,
their conversion to enantio-enriched alternative complex ring
systems will be reported in the future. Here we decided to
continue the development of a route to 2 using the much larger
quantities of ()-6 available to us.
With the novel ketone 6 in hand, the ketone functionality was
converted to the corresponding epoxide using ClCH2I
16 (see
Scheme S2 (ESI†) for the stereochemical assignment of 16).13
Allylsilylation of 16 under Lewis acidic conditions with allylTMS
(17) in a modified Hosomi–Sakurai reaction11 gave the desired
alcohol 5 as a single diastereoisomer (as judged by 1H NMR
analysis of the crude reactionmixture). This reaction proved highly
robust and scalable with ca. 42 g of 16 being reproducibly
converted to 38 g of 5. X-ray crystallographic analysis of 5 con-
firmed the required anti-relationship of the two allyl substituents
at C-10b and C-11 (Scheme 4 and Scheme S3, ESI†).13
The challenge of selectively functionalising the two allyl groups
in 5 now had to be overcome. A two-step oxidation of 5, followed
by regioselective iodolactonisation gave 18 and its epimer at the
indicated carbon as an inconsequential mixture of diastereo-
isomers (Scheme 5, d.r. 3 : 1). The relative configuration of the
newly formed stereocentre in themajor isomer 18was determined
by nOe analysis (Scheme S4 and Fig. S2–S4, ESI†).13 Oxidative
cleavage on treatment with catalytic OsO4 and NMO followed by
in situ reaction with PhI(OAc)2 gave 19 and its epimer (Scheme 5
and Scheme S5, ESI†).13 After incorporation of the required
nitrogen by reductive amination using ()-1217 (Scheme 3),
retro-iodolactonisation to give the diastereomeric mixture 20,
acid-mediated deprotection and subsequent treatment of 21 with
HBTU and DIPEA, lactam 4 was obtained. However, cyclisation
Scheme 2 Construction of key intermediate 6: (a) NCS, DMP, DCM, 0 1C,
2 h; then TCA, 0 1C – rt, 2 h, 93%; (b) Ph2O, reflux, 2.5 h, 79%; (c) POCl3,
reflux, 95%; (d) Na (3 eq.), allyl alcohol (5.7 eq.), rt, 18 h, 92%; (e) PhMe,
reflux, 1.5 h, 88%.
Scheme 3 Obtaining the (R) and (S) enantiomers of ketone 6 from their
respective imines 13 and 14. The ORTEP representation of 15 is also shown
and was used to infer the absolute configuration of 14 and (S)-6 (and
hence 13 and (R)-6). Reagents and conditions: (a) R-(12) (10 eq.), Ti(OEt)4
(15 eq.), toluene, 85 1C, 9 h; (b) 12 M HCl, MeOH, rt, 0.5 h; (c) NaBH4
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of 20 to 4 proved irreproducible (for further discussion see
Schemes S6–S8 and Fig. S5, ESI†).13 An alternative route to 4 was
investigated in an attempt to circumvent the reproducibility issue.
Di-allyl alcohol 5 underwent a regio- and highly diastereo-selective
iodoetherification to give 22 (and its epimer, d.r. 11 : 1, Fig. S6,
ESI†)13 in the presence of iodine under basic conditions. A one-pot
oxidative cleavage of the alkene gave 23 (and its epimer) which
underwent successful reductive amination with (R)-12 followed by
a retro-iodoetherification in the presence of Zn to generate the
diastereomeric mixture 24. Oxidation of 24 with the Dess–Martin
periodinane18 gave 25 in a reasonable yield (52%) for this relatively
complex process which also involves acid-mediated deprotection
of the sulfinamide. Interestingly, 25 underwent oxidation with
NaClO2 to give the required lactam 4. This transformation was
inspired by a report by Tomioka et al. on an unrelated system.19
The new approach was robust and overall reduced the length of
the reaction sequence to 4.
Having successfully synthesised the desired lactam 4, its
conversion to 2 was completed (Scheme 6). The remaining alkene
in lactam 4 was oxidatively cleaved and the resulting aldehyde
reductively aminated using MeNH2HCl under basic conditions to
give 26 (Scheme 6). Boc protection of 26 gave 27 which underwent
alkylation with Meerwein’s reagent20 to give 28.13 Deprotection of
28 with trifluoroacetic acid gave 29 which cyclised on refluxing
in toluene to give N-benzyl-dehaloperophoramidine (30) in
excellent yield. X-ray crystallographic analysis of 30 confirmed
the successful formation of the C-40 amidine motif.15 The
synthesis of 2 was completed by N-benzyl deprotection of 30
via a single electron transfer process with a freshly prepared
solution of sodium naphthalenide.21
Synthetic 2 was converted to the corresponding TFA salt13 and
compared to an authentic sample of 2TFA (Fig. S7–S9, ESI†).13
A doping experiment with authentic 2TFA and synthetic 2TFA
confirmed that the desired compound had been successfully
prepared (see Fig. S8A and B, ESI† for a comparison of a selected
region of the 1H NMR analysis carried out in CD3OD). Super-
imposition of the 1H NMR of the doped sample with the
Scheme 4 Construction of all-carbon quaternary stereocentres. The ORTEP
representation of 5 is also shown.15 Reagents and conditions: (a) ClCH2I
(1.1 eq.), MeLiBr (2.2 M solution in Et2O, 1.5 eq.), THF, 78 1C, 2 h; (b) allylTMS
(17) (2.5 eq.), TiCl4 (4 eq.), DCM, 78 1C, 78% (2 steps).
Scheme 5 Two alternative approaches to lactam 4. Reagents and con-
ditions: (a) PCC (1.1 eq.) DCM, rt, 16 h; (b) Jones reagent (1.5 eq.), acetone, rt,
16 h; (c) NIS (1.1 eq.), NaHCO3 (1.1.eq.), DCM, rt, 16 h, d.r. 3 : 1, 47%, (over 5 steps
from 7); (d) OsO4 (0.13 mol%), NMO (1.5 eq.), acetone/H2O (10 : 1), rt, 18 h, then
PhI(OAc)2 (1.5 eq.), rt, 1.5 h, 86%; (e) ()-12 (1.1 eq.), TiOEt4 (3 eq.) CHCl3, rt,
16 h, then NaBH4 (4 eq. in MeOH), 0.5 h, rt, 75%; (f) Zn, EtOH, reflux, 16 h, 89%;
(g) 4 M HCl in dioxane/MeOH (10 : 1), rt, 1 h, then HBTU (1.5 eq.) and DIPEA
(5 eq.), 16 h, 71%; (h) I2 (2.5 eq.), K2CO3 (2.5 eq.), rt, MeCN, 16 h, d.r. 11 : 1, 96%;
(i) OsO4 (0.19 mol%), NMO (1.5 eq.), THF :H2O (9 : 1), rt, 16 h, then PhI(OAc)2
(1.5 eq.), rt, 2 h, 66%; (j) (R)-16 (1.1 eq.), Ti(OEt)4 (2 eq.), CHCl3, rt, 16 h, then
NaBH4 (5 eq.) in MeOH, rt, 1 h, 68%; (k) Zn (31 eq.), EtOH, reflux, 16 h, 80%;
(l) Dess–Martin periodinane (1.5 eq.), DCM, rt, 0.5 h, 52%, (m) NaClO2 (2.5 eq.),
NaH2PO4 (5 eq.), 2-methylbuten-2-ene (10 eq.), THF/H2O (1.5 : 1), rt, 2 h, 58%.
Scheme 6 Completion of the synthesis of ()-2. Reagents and condi-
tions: (a) OsO4 (3.2 mol%), NMO (1.5 eq.), THF/H2O, rt, 16 h, then PhI(OAc)2
1.5 h, 62% (over 2 steps from 25); (b) MeNH2HCl (2.5 eq.), NaOAc (2.5 eq.),
MeOH, rt, 16 h, then NaBH4 (3 eq.), rt, 0.5 h; (c) (Boc)2O (1.5 eq.), TEA
(1.5 eq.), rt, 1 h, 44% (2 steps); (d) Meerwein’s reagent (1 M solution in DCM,
8 eq.), DIPEA (8 eq.), DCM, 0 1C – rt, 2 h, 72%; (e) 5% TFA, DCM, 0 1C, 0.5 h;
(f) DIPEA (2 eq.), toluene, reflux, 16 h, 83% (over 2 steps); (g) Na/naphthalene
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1H NMR of authentic 2TFA alone displayed enhancement of the
signals corresponding to the product whilst an impurity from
authentic 2TFA remained unchanged (Fig. S8C for selected aryl
and Fig. S8D for alkyl signals, ESI†).13
When reanalysed in CDCl3, our sample of 2TFA gave chemical
shifts analogous to those previously reported (Table S2, ESI†).13
Comparison of the 1H NMR analysis of our synthetic free base 2
in CDCl3 was also consistent with the previous literature
(Table S3, ESI†).13
Preliminary biological activity associated with 1 has been
reported by Ireland et al.,1 however, no information on the activity
of 2 is available. Therefore our sample of 2 was tested against the
same cancer cell line (HCT116) used to assess the activity of 1
(Fig. 2). Estimation of an IC50 inhibitory concentration showed
that 2 killed HCT116 cells with similar potency to 1, suggesting
that the halogens present in 1 are not essential for biological
activity. Analogous studies using the colorectal cancer lines HT29
and LoVo showed that both were more sensitive to 2 than the
HCT116 cells. Attempts to test the synthetic precursor N-benzyl-
dehaloperophoramidine (30) proved diﬃcult due to its insolubility
at the concentrations used in these assays.
In conclusion, a synthesis of dehaloperophoramidine (2) from
commercially available starting materials has been achieved.
A highly eﬃcient [3,3]-Claisen rearrangement to give novel
ketone 6 was followed by a diastereoselective epoxide opening/
allylsilylation (modified Hosomi–Sakurai) reaction. In combination
these reaction enabled construction of the required contiguous
all carbon quaternary stereocentres. Detailed spectroscopic
comparison with an authentic sample of 2 confirmed that it
was identical to our synthetic TFA salt of 2. Preliminary
biological activity associated with 2 has also been reported for
the first time.
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Fig. 2 Dose–response curves for the effect of our synthetic sample of 2
on the growth of three colorectal cancer cell lines. Growth data (relative
to untreated controls but containing equimolar concentrations of DMSO
carrier) are shown for HCT116 (solid line), HT29 (dashed line) and LoVo
cells (dotted line), assessed by SRB assay four days after treatment. The
number of cells plated per well at the beginning of the experiment is
shown in parentheses. IC50 values of 60–70 mM (HCT116), 60 mM (HT29)
and 50 mM (LoVo) were calculated using Graphpad Prism software and are
equivalent to the IC50 of 60 mM reported for compound 1 by Ireland et al.
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